Lambert-Eaton myasthenic syndrome: From clinical characteristics to therapeutic strategies

The Lancet Neurology

Volumn 10, Issue 12, 2011, Pages 1098-1107

  Titulaer, Maarten J ^a,b   Lang, Bethan ^c   Verschuuren, Jan JGM ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; AUTOANTIBODY; AZATHIOPRINE; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; CISPLATIN; ETOPOSIDE; IMMUNOGLOBULIN; MUSCARINIC M1 RECEPTOR; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB; TRANSCRIPTION FACTOR SOX1 ANTIBODY; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED CALCIUM CHANNEL ANTIBODY;

ABNORMAL SENSATION; AUTONOMIC DYSFUNCTION; CANCER DIAGNOSIS; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DIGITAL PARESTHESIA; DISEASE ASSOCIATION; EATON LAMBERT SYNDROME; ELECTROMYOGRAPHY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEART INFARCTION; HUMAN; LUNG SMALL CELL CANCER; LYMPHOPROLIFERATIVE DISEASE; MUSCLE ACTION POTENTIAL; NERVE STIMULATION; PARANEOPLASTIC SYNDROME; PATHOPHYSIOLOGY; PERIORAL TINGLING; PERIPHERAL NERVOUS SYSTEM; PLASMAPHERESIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; QT PROLONGATION; REVIEW; SCREENING; SEIZURE; TENDON REFLEX; THYMOMA;

4-AMINOPYRIDINE; AUTOANTIBODIES; CALCIUM CHANNELS; CARCINOMA, SMALL CELL; HUMANS; LAMBERT-EATON MYASTHENIC SYNDROME; LUNG NEOPLASMS;

EID: 81255211667     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70245-9     Document Type: Review

References (101)

1. Anderson HJ, Churchill-Davidson HC, Richardson AT Bronchial neoplasm with myasthenia-prolonged apnoea after administration of succinylcholine. Lancet 1953, 265:1291-1293.
2. Lambert EH, Eaton LM, Rooke ED Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol 1956, 187:612-613.
3. Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol 2011, 29:902-908.
4. Wirtz PW, Nijnuis MG, Sotodeh M, et al. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol 2003, 250:698-701.
5. O'Neill JH, Murray NMF, Newsom-Davis J The Lambert-Eaton myasthenic syndrome-a review of 50 cases. Brain 1988, 111:577-596.
6. Sanders DB Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies. Ann Neurol 1995, 37(suppl 1):63-73.
7. Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg 2002, 104:359-363.
8. Vincent A, Clover L, Buckley C, Grimley EJ, Rothwell PM Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 2003, 74:1105-1108.
9. Wirtz PW, Willcox N, van der Slik AR, et al. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol 2005, 159:230-237.
10. Giraud M, Beaurain G, Yamamoto AM, et al. Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology 2001, 57:1555-1560.
11. Gutmann L, Crosby TW, Takamori M, Martin JD The Eaton-Lambert syndrome and autoimmune disorders. Am J Med 1972, 53:354-356.
12. Wirtz PW, Bradshaw J, Wintzen AR, Verschuuren JJ Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families. J Neurol 2004, 251:1255-1259.
13. Elmqvist D, Lambert EH Detailed analysis of neuromuscular transmission in a patient with myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clinic Proc 1968, 43:689-713.
14. Nakao YK, Motomura M, Fukudome T, et al. Seronegative Lambert-Eaton myasthenic syndrome. Neurology 2002, 59:1773-1775.
15. Tim RW, Massey JM, Sanders DB Lambert-Eaton myasthenic syndrome: electrodiagnostic finding and response to treatment. Neurology 2000, 54:2176-2178.
16. Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 2008, 26:4276-4281.
17. Wirtz PW, van Dijk JG, van Doorn PA, et al. The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands. Neurology 2004, 63:397-398.
18. Titulaer MJ, Verschuuren JJ Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. Ann NY Acad Sci 2008, 1132:129-134.
19. Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001, 124:1138-1148.
20. Fernandez-Torron R, Arcocha J, Lopez-Picazo JM, et al. Isolated dysphagia due to paraneoplastic myasthenic syndrome with anti-P/Q-type voltage-gated calcium-channel and anti-acetylcholine receptor antibodies. Neuromuscul Disord 2011, 21:126-128.
21. Lauritzen M, Smith T, Fischer-Hansen B, Sparup J, Olesen J Eaton-Lambert syndrome and malignant thymoma. Neurology 1980, 30:634-638.
22. Morimoto M, Osaki T, Nagara Y, Kodate M, Motomura M, Murai H Thymoma with Lambert-Eaton myasthenic syndrome. Ann Thorac Surg 2010, 89:2001-2003.
23. Pasqualoni E, Aubart F, Brihaye B, et al. Lambert-Eaton myasthenic syndrome and follicular thymic hyperplasia in systemic lupus erythematosus. Lupus 2011, 20:745-748.
24. Homenda W, Hellmann A Hodgkin's disease with systemic vasculitis and Lambert-Eaton myasthenic syndrome-case report. Wiad Lek 2000, 53:574-578. (in Polish).
25. Argov Z, Shapira Y, Averbuch-Heller L, Wirguin I Lambert-Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders. Muscle Nerve 1995, 18:715-719.
26. Portha C, Dupond JL, Monnier G, Bosset JF, Desfloris RL Eaton Lambert syndrome associated with multiple-myeloma-resolution of the neuromuscular block after chemotherapy. Semaine des Hopitaux 1983, 59:1337-1339.
27. Wohl MA, Wood JK Chronic myeloid leukemia and a myasthenic syndrome. Acta Haematologica 1979, 62:214-218.
28. Titulaer MJ, Wirtz PW, Kuks JB, et al. The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. J Neuroimmunol 2008, 201-02:153-158.
29. Wirtz PW, Wintzen AR, Verschuuren JJ Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer. Muscle Nerve 2005, 32:226-229.
30. Burns TM, Russell JA, LaChance DH, Jones HR Oculobulbar involvement is typical with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003, 53:270-273.
31. Lorenzoni PJ, Scola RH, Kay CS, Parolin SF, Werneck LC Non-paraneoplastic Lambert-Eaton myasthenic syndrome: a brief review of 10 cases. Arq Neuropsiquiatr 2010, 68:849-854.
32. Pellkofer HL, Armbruster L, Linke R, Schumm F, Voltz R Managing non-paraneoplastic Lambert-Eaton myasthenic syndrome: clinical characteristics in 25 German patients. J Neuroimmunol 2009, 217:90-94.
33. Titulaer MJ, Wirtz PW, Wintzen AR, Verschuuren JJGM Lambert-Eaton myasthenic syndrome with pure ocular weakness. Neurology 2008, 70:86.
34. Wirtz PW, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2002, 73:766-768.
35. Oh SJ The Eaton-Lambert syndrome in ocular myasthenia gravis. Arch Neurol 1974, 31:183-186.
36. Rudnicki SA Lambert-Eaton myasthenic syndrome with pure ocular weakness. Neurology 2007, 68:1863-1864.
37. Smith AG, Wald J Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine. Neurology 1996, 46:1143-1145.
38. Odabasi Z, Demirci M, Kim DS, et al. Postexercise facilitation of reflexes is not common in Lambert-Eaton myasthenic syndrome. Neurology 2002, 59:1085-1087.
39. Oh SJ, Kurokawa K, Claussen GC, Ryan HF Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 2005, 32:515-520.
40. van Doorn PA, Ruts L, Jacobs BC Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol 2008, 7:939-950.
41. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011, 377:942-955.
42. Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement. Muscle Nerve 2001, 24:1236-1238. AAEM Quality Assurance Committee.
43. Tim RW, Massey JM, Sanders DB Lambert-Eaton myasthenic syndrome (LEMS)-clinical and electrodiagnostic features and response to therapy in 59 patients. Ann N Y Acad Sci 1998, 841:823-826.
44. Hatanaka Y, Oh SJ Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome. Muscle Nerve 2008, 37:572-575.
45. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995, 332:1467-1474.
46. Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsomdavis J Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 1997, 147:35-42.
47. Takamori M, Takahashi M, Yasukawa Y, et al. Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome. J Neurol Sci 1995, 133:95-101.
48. Titulaer MJ, Klooster R, Potman M, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 2009, 27:4260-4267.
49. Johnston I, Lang B, Leys K, Newsom-Davis J Heterogeneity of calcium channel autoantibodies detected using a small-cell lung cancer line derived from a Lambert-Eaton myasthenic syndrome patient. Neurology 1994, 44:334-338.
50. Martin-Moutot N, De HL, Seagar M Distinct evolution of calcium channel antibody types in Lambert-Eaton myasthenic syndrome. J Neuroimmunol 2008, 197:47-53.
51. Martin-Moutot N, Haro L, Santos RG, Mori Y, Seagar M Phoneutria nigriventer omega-Phonetoxin IIA: a new tool for anti-calcium channel autoantibody assays in Lambert-Eaton myasthenic syndrome. Neurobiol Dis 2006, 22:57-63.
52. Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, Vincent A P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002, 59:764-766.
53. Parsons KT, Kwok WW Linear B-cell epitopes in Lambert-Eaton myasthenic syndrome defined by cell-free synthetic peptide binding. J Neuroimmunol 2002, 126:190-195.
54. Takamori M, Iwasa K, Komai K Antibodies to synthetic peptides of the alpha1A subunit of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. Neurology 1997, 48:1261-1265.
55. Pellkofer HL, Armbruster L, Krumbholz M, et al. Lambert-Eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel. J Neuroimmunol 2008, 204:136-139.
56. Verschuuren JJ, Dalmau J, Tunkel R, et al. Antibodies against the calcium channel beta-subunit in Lambert-Eaton myasthenic syndrome. Neurology 1998, 50:475-479.
57. Lecky BR Transient neonatal Lambert-Eaton syndrome. J Neurol Neurosurg Psychiatry 2006, 77:1094.
58. Reuner U, Kamin G, Ramantani G, Reichmann H, Dinger J Transient neonatal Lambert-Eaton syndrome. J Neurol 2008, 255:1827-1828.
59. Komai K, Iwasa K, Takamori M Calcium channel peptide can cause an autoimmune-mediated model of Lambert-Eaton myasthenic syndrome in rats. J Neurol Sci 1999, 166:126-130.
60. Kaja S, Van de Ven RC, van Dijk JG, et al. Severely impaired neuromuscular synaptic transmission causes muscle weakness in the Cacna1a-mutant mouse rolling Nagoya. Eur J Neurosci 2007, 25:2009-2020.
61. Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996, 47:678-683.
62. Newsom-Davis J, Murray NM Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984, 34:480-485.
63. Lang B, Newsom-Davis J, Peers C, Wray DW Selective action of Lambert-Eaton myasthenic syndrome antibodies on Ca-2+ channels in the neuroblastoma x glioma hybrid cell-line Ng108-15. J Physiol Lond 1987, 394:43.
64. Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci USA 1983, 80:7636-7640.
65. Prior C, Lang B, Wray D, Newsom-Davis J Action of Lambert-Eaton myasthenic syndrome IgG at mouse motor nerve terminals. Ann Neurol 1985, 17:587-592.
66. Roberts A, Perera S, Lang B, Vincent A, Newsom-Davis J Para-neoplastic myasthenic syndrome IgG inhibits Ca-45(2+) flux in a human small cell carcinoma line. Nature 1985, 317:737-739.
67. Pinto A, Iwasa K, Newland C, Newsom-Davis J, Lang B The action of Lambert-Eaton myasthenic syndrome immunoglobulin G on cloned human voltage-gated calcium channels. Muscle Nerve 2002, 25:715-724.
68. Giovannini F, Sher E, Webster R, Boot J, Lang B Calcium channel subtypes contributing to acetylcholine release from normal, 4-aminopyridine-treated and myasthenic syndrome auto-antibodies-affected neuromuscular junctions. Br J Pharmacol 2002, 136:1135-1145.
69. Chen J, Billings SE, Nishimune H Calcium channels link the muscle-derived synapse organizer laminin beta2 to Bassoon and CAST/Erc2 to organize presynaptic active zones. J Neurosci 2011, 31:512-525.
70. Nishimune H, Sanes JR, Carlson SS A synaptic laminin-calcium channel interaction organizes active zones in motor nerve terminals. Nature 2004, 432:580-587.
71. Fukuda T, Motomura M, Nakao Y, et al. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003, 53:21-28.
72. Oh SJ, Hatanaka Y, Claussen GC, Sher E Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome. Muscle Nerve 2007, 35:178-183.
73. el Far O, Marqueze B, Leveque C, et al. Antigens associated with N- and L-type calcium channels in Lambert-Eaton myasthenic syndrome. J Neurochem 1995, 64:1696-1702.
74. Takamori M, Hamada T, Komai K, Takahashi M, Yoshida A Synaptotagmin can cause an immune-mediated model of Lambert-Eaton myasthenic syndrome in rats. Ann Neurol 1994, 35:74-80.
75. Takamori M, Motomura M, Fukudome T, Yoshikawa H Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders. Eur J Neurol 2007, 14:1230-1235.
76. Sabater L, Titulaer M, Saiz A, Verschuuren J, Gure AO, Graus F SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2008, 70:924-928.
77. Stich O, Klages E, Bischler P, et al. SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes. Acta Neurol Scand 2011, published online Jul 14. 10.1111/j.1600-0404.2011.01572.
78. Tschernatsch M, Singh P, Gross O, et al. Anti-SOX1 antibodies in patients with paraneoplastic and non-paraneoplastic neuropathy. J Neuroimmunol 2010, 226:177-180.
79. Vural B, Chen LC, Saip P, et al. Frequency of SOX group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer 2005, 103:2575-2583.
80. Dongradi G, Poisson M, Beuve-Mery P, Fendler JP, Buge A, Fritel D Association of a lung cancer and several paraneoplastic syndromes (Lambert-Eaton syndrome, polymyositis and Schwartz-Bartter syndrome). Ann Med Interne (Paris) 1971, 122:959-964. (in French).
81. Ramos-Yeo YL, Reyes CV Myasthenic syndrome (Eaton-Lambert syndrome) associated with pulmonary adenocarcinoma. J Surg Oncol 1987, 34:239-242.
82. Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011, 18:19-e3.
83. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010, 17:893-902.
84. Vedeler CA, Antoine JC, Giometto B, et al. Paraneoplastic neurological syndromes. European Handbook of Neurological Management 2011, 447-457. Blackwell Publishing Ltd, Oxford. 2nd edn. N.E. Gilhus, M.P. Barnes, M. Brainin (Eds.).
85. Keogh M, Sedehizadeh S, Maddison P Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2011, CD003279.
86. McEvoy KM, Windebank AJ, Daube JR, Low PA 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989, 321:1567-1571.
87. Oh SJ, Claussen GG, Hatanaka Y, Morgan MB 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve 2009, 40:795-800.
88. Sanders DB, Massey JM, Sanders LL, Edwards LJ A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000, 54:603-607.
89. Wirtz PW, Verschuuren JJ, van Dijk JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther 2009, 86:44-48.
90. Lindquist S, Stangel M Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat 2011, 7:341-349.
91. Boerma CE, Rommes JH, van Leeuwen RB, Bakker J Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome. J Toxicol Clin Toxicol 1995, 33:249-251.
92. Lundh H, Nilsson O, Rosen I, Johansson S Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome. Acta Neurol Scand 1993, 88:136-140.
93. Molgo J, Lundh H, Thesleff S Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur J Pharmacol 1980, 61:25-34.
94. Wu ZZ, Li DP, Chen SR, Pan HL Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit. J Biol Chem 2009, 284:36453-36461.
95. Oh SJ, Kim DS, Head TC, Claussen GC Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome. Muscle Nerve 1997, 20:1146-1152.
96. Maddison P, Lang B, Mills K, Newsom-Davis J Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry 2001, 70:212-217.
97. Palace J, Newsom-Davis J, Lecky B A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998, 50:1778-1783.
98. Janssen-Heijnen ML, Maas HA, Siesling S, Koning CC, Coebergh JW, Groen HJ Treatment and survival of patients with small-cell lung cancer: small steps forward, but not for patients >80. Ann Oncol 2011, published online June 20. 10.1093/annonc/mdr303.
99. Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990, 40:1552-1556.
100. Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011, 82:671-673.
101. Pellkofer HL, Voltz R, Kuempfel T Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction. Muscle Nerve 2009, 40:305-308.